Healthcare organizations are accelerating their use of artificial intelligence while struggling to reconcile a widening assortment of privacy, security and AI governance requirements across jurisdictions, according to participants in a Sept. 8 webinar describing a healthcare AI global regulatory patchwork that is complicating everything from drug development to patient care tools.
Why This Healthcare AI Global Regulatory Patchwork Challenge Is Particularly Acute
Participants in the webinar, hosted by the Atlantic Council’s Cyber Statecraft Initiative, warned that conflicting rules governing data use, infrastructure and cross-border transfers could impede clinical trials, pharmaceutical research and the development of tools intended to improve patient care, according to an account by the International Association of Privacy Professionals. The tension is particularly acute in healthcare because AI systems often require large quantities of sensitive and diverse patient information, restricting access can undermine model quality, but processing it exposes organizations to overlapping regulatory obligations and potentially serious consequences if safeguards fail.
Why Safeguards Matter for Population-Level Benefit
“When we develop an AI model, the goal is to drive a benefit for a population,” said Ranjit Kumble, VP of enterprise data science and advanced analytics at Pfizer. “If a model is deployed without the right safeguards, the benefit to the population is much, much more uneven.”
The Specific Jurisdictional Conflicts Within This Healthcare AI Global Regulatory Patchwork
Artificial intelligence is helping pharmaceutical researchers identify biological targets during the early stages of drug development, Kumble said, but companies operating internationally must navigate different approaches in China, the European Union and the U.S., along with conflicts among sector-specific and state laws within the U.S. itself.
How the EU and U.S. Frameworks Diverge
In Europe, healthcare developers may need to account for both the EU General Data Protection Regulation and the EU AI Act, including its requirements for certain high-risk systems. In the U.S., organizations face a more fragmented framework encompassing health privacy rules, state consumer privacy statutes and AI laws that may emphasize disclosures or chatbot transparency rather than the risk-management obligations found in Europe.
The Scalability Problem Within This Healthcare AI Global Regulatory Patchwork
This fragmentation creates a practical scalability problem, according to the participants. Kumble said organizations often prepare datasets separately for individual AI projects to ensure the information is “AI ready.” Repeating that work as use cases multiply can become both unsustainable and unscalable.
Why This Burden Extends Beyond Compliance Teams
The burden is not limited to compliance teams. Different restrictions on sensitive-data processing can determine whether researchers obtain data of sufficient breadth, depth and quality to train reliable systems, affecting product performance, patient confidence and a company’s ability to compete in an increasingly precise and data-intensive healthcare market.
Why Governance Must Adapt to Agentic AI Within This Healthcare AI Global Regulatory Patchwork
The webinar also highlighted the need for governance systems capable of adapting as AI technology changes. Daria Bahrami, head of policy at AI cybersecurity company Dreadnode, said faster AI-driven results are forcing companies to make real-time decisions about their tolerance for risks that previously remained in the background. Flexibility, however, should not displace baseline controls, she said, and organizations should assess data processing, retention and other governance requirements before deploying a tool.
The Specific Risks Agentic AI Introduces
This is becoming more important as healthcare companies experiment with agentic AI systems capable of taking actions with limited human involvement. The risks include agents exceeding their intended permissions or escaping controlled testing environments. Stephen Moon, Snowflake’s global public sector chief technology officer, said organizations must limit agents at both the governance and data-security levels, since an agent’s potential reach depends heavily on the systems and information it is permitted to access.
Why Agent Access Controls Are Also Patient-Safety Issues
For healthcare providers and technology vendors, this makes access controls, data segmentation and continuous monitoring patient-safety issues as well as cybersecurity obligations. A compromised artificial intelligence agent with access to medical records, diagnoses or prescription systems could cause substantially greater harm than a conventional data leak.
Why Healthcare Organizations Can’t Wait for Regulatory Harmonization
The business takeaway is that healthcare organizations cannot wait for regulators to harmonize their rules. They need inventories of AI uses and applicable laws, documented pre-deployment reviews, strict limits on agent permissions and governance structures that can accommodate jurisdiction-specific requirements without rebuilding compliance programs for every project. They also need incident-communications plans grounded in verified facts, since Kumble warned that disproportionate or poorly informed coverage of an AI incident can generate panic, making an already difficult event even harder to contain.
What This Healthcare AI Global Regulatory Patchwork Means Going Forward
Given the scalability problem Kumble described, where organizations must repeatedly prepare separate AI-ready datasets for individual projects, healthcare companies operating across multiple jurisdictions may need to invest in more centralized, reusable data governance infrastructure rather than continuing to treat each AI use case as a standalone compliance exercise. Given the specific agentic AI risks Moon and Bahrami raised, healthcare organizations piloting autonomous AI systems should prioritize permission-limiting and data-segmentation controls before deployment rather than treating governance as a retrofit once agents are already operating within clinical or administrative workflows.
What to Watch Going Forward
As healthcare organizations continue navigating this fragmented regulatory landscape, industry observers will likely watch whether international bodies make meaningful progress toward harmonizing AI governance standards, or whether the divergence between the EU’s risk-management-focused approach and the U.S.’s disclosure-focused framework continues widening. Given the panel’s shared conclusion that companies cannot simply wait for regulators to resolve these conflicts, this healthcare AI global regulatory patchwork challenge may increasingly shape which healthcare AI vendors and pharmaceutical companies succeed in building genuinely scalable, cross-border compliance programs versus those that remain constrained by jurisdiction-specific, one-off data preparation processes.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed
